Emerging role of vesicular carriers for therapy of visceral leishmaniasis: Conventional versus novel

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 27, Issue 6, 2010, Pages 461-507

  Kumar, Navneet ^a   Gupta, Swati ^a   Dube, Anuradha ^b   Vyas, Suresh P ^c  

^a ISF COLLEGE OF PHARMACY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c DR H S GOUR UNIVERSITY   (India)

Author keywords

Active targeting; Combination therapy; Nanocarriers; Passive targeting; Vesicular systems; Visceral leishmaniasis

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; ANTIMONY GLUCONATE; ARGININE; ATOVAQUONE; DRUG CARRIER; FLUCYTOSINE; GAMMA INTERFERON; GRISEOFULVIN; INDOLYLQUINOLINE DERIVATIVE A; INTRALIPID; KETOCONAZOLE; KUTKIN; LEVAMISOLE; LIPOSOME; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; POLYINOSINIC POLYCYTIDYLIC ACID; QUINOLINE DERIVATIVE; SITAMAQUINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANADIC ACID;

ABDOMINAL PAIN; AMASTIGOTE; ANEMIA; ARTHRALGIA; CARDIOTOXICITY; CLINICAL TRIAL; COLLOID; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TREATMENT FAILURE; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEPHROTOXICITY; LIPID COMPLEX; LIPID COMPLEX; NEUROTOXICITY; NONHUMAN; PANCREATITIS; PARASITE TRANSMISSION; PHLEBITIS; PROMASTIGOTE; REVIEW; SINGLE DRUG DOSE; TERATOGENICITY; VESTIBULOCOCHLEAR NERVE DISEASE; VISCERAL LEISHMANIASIS; VOMITING;

EID: 78650046007     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v27.i6.10     Document Type: Review

References (156)

1. Singh S. New developments in diagnosis of leishmaniasis. Indian J Med Res. 2006;123(3):311-30.
2. Pandey HP, Singh RK, Sundar S. Visceral leishmaniasis (kala-azar): challenges ahead. Indian J Med Res. 2006;123(4):331-44.
3. Chappius F, Sundar S, Hailu A Ghalib A, Rijal S, Peeling RW, Alvar J, Boelaert M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007;5(11):873-82.
4. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27(5):305-18. (Pubitemid 38842803)
5. Singh S, Mishra J, Saxena A. Chemotherapy of leishmaniasis: past, present and future. Current Medicinal Chemistry. 2007;14(10):1153-69.
6. Kumari S, Kumar A, Samant M, Singh N, Dube A. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics. Curr Drug Targets. 2008;9(11):938-47.
7. Alvar J, Canavate C, Gutierrez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, Molina R, Moreno J. Leishmania and human immunodeficiency virus coinfection: the first. 10 years. Clin Microbiol Rev. 1997;10(2):298-319.
8. Vyas SP, Gupta S. Optimizing efficacy of amphotericin B through nanomodification. Int J Nanomed. 2006;1(4):417-32.
9. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo Dl, Jameson JL. Harrison's Manual of Medicine. New York: McGraw-Hill; 2001.
10. Gupta S, Pal A, Vyas SP. Drug delivery strategies for visceral leishmaniasis. Expert Opin Drug Deliv. 2010;7(3):371-402.
11. Croft SL. In-vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasis. Parasitol Today. 1986;2(3):64-9.
12. Minutes of the meeting of the Expert Committee for the treatment of Kala-azar in India. 2000.
13. Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opin Pharmacother. 2005;6(16): 2821-9.
14. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PCK, Murray HW. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis. 2000;31(4):1104-7.
15. Berman J. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis. 2003;16(5): 397-401.
16. Singh S, Sivakumar R. Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother. 2004;10(6):307-15.
17. Santos OD, Coutinho ERC, Madeira FM, Bottino CG, Vieira RT, Nascimento SB, Bernardino A, Bourguignon SC, Corte-Real S, Pinho RT, Rodrigues CR, Castro HC. Leishmaniasis treatment-a challenge that remains: a review. Parasitol Res. 2008;103(1):1-10.
18. Frézard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: new perspectives for old drugs. Molecules. 2009;14(7):2317-36.
19. Wyllie S, Cunningham ML, Fairlamb AH. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem. 2004;279(38):39925-32. (Pubitemid 39258265)
20. Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Ind J Med Res. 2006;123(3):345-52. (Pubitemid 43905574)
21. Simon L Croft, Graham H Coombs. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003;19(11):502-8.
22. Basselin M, Denise H, Coombs GH. Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob Agents Chemother. 2002;46(12):3731-8. (Pubitemid 35403244)
23. Paris C, Loiseau PM, Bories C, Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother. 2004;48(3):852-9.
24. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resistance Updates. 2004;7(4-5):257-66.
25. Yeates C. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr Opin Investig Drugs. 2002;3:1446-52.
26. Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem. 2003;278(50):49965-71.
27. Perez-Victoria JM, Perez-Victoria FJ, Parodi-Talice A, Jimenez IA, Ravelo AG, Castanys S, Gamarro F. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob Agents Chemother. 2001;45(9):2468-74. (Pubitemid 32801897)
28. Coelho AC, Beverley SM, Cotrim PC. Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major. Mol Biochem Parasitol. 2003;130(2):83-90.
29. Roberts CW, McLeod R, Rice DW, Ginger M, Chance ML, Goad LJ. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol. 2003;126(2):129-42. (Pubitemid 36255612)
30. Mbongo N, Loiseau PM, Billion MA, Robert-Gero M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob Agents Chemother. 1998;42(2):352-7. (Pubitemid 128505055)
31. Hastings IM. Modelling parasite drug resistance: lessons for management and control strategies. Trop Med Int Health. 2001;6(11):883-90.
32. Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet infect dis. 2010;10(3):184-94.
33. Chunge CN, Gachihi G, Muigai R. Visceral leishmaniasis unresponsive to antimonials drugs. III. Successful treatment using combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg. 1985;7(5):715-8.
34. Ragusa R, Di Cataldo A, Samperi P, Schiliro G. Treatment of visceral leishmaniasis with meglumine and allopurinol. Am J Dis Child. 1993;147:611-2.
35. Marty P, Rosenthal E. Treatment of visceral leishmaniasis: a review of current treatment practices. Expert Opin Pharmacother. 2002;3(8):1101-8.
36. Den Boer ML, Alvar J, Davidson RN, Retmeijer K, Balasegaram M. Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs. 2009;14(3):395-410.
37. Murray HW, Hariprashad J. Activity of oral atavaquone alone and in combination with antimony in experimental visceral leishmaniasis. Antimicrob Agents and Chemother. 1996;40(3):586-7.
38. Bhakuni V, S Kulkarni, V Ali, Singh UK, Levy HB, Maheshwari RK. Immunotherapy for Leishmania donovani infection in golden hamsters: combinatorial action of poly ICLC plus L-arginine and sodium stibogluconate (stibanate). J Interferon Cytokine Res. 1999;19(10):1103-6.
39. Pal C, Raha M, Basu A, Roy KC, Gupta A, Ghosh M, Sahu NP, Banerjee S, Mandal NB, Bandyopadhyay. Combination therapy with indolylquinoline derivative and sodium antimony gluconate cures established visceral leishmaniasis in hamsters. Antimicrob Agents Chemother. 2002;46(1):259-61.
40. Gupta S, Sharma SC, Srivastava VML. Efficacy of picroliv in combination with milltefosine, an orally effective anti-leishmanial drug against experimental visceral leishmaniasis. Acta Tropica. 2005;94(1):41-7. (Pubitemid 40445378)
41. Denerolle P, Bourdoiseau G. Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases). J Vet Int Med. 1999;13(5):413-5.
42. Haldar AK, Banerjee S, Naskar K, Kalita D, Islam NS, Roy S. Sub-optimal dose of Sodium Antimony Gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant Leishmania donovani by expanding anti-leishmanial T-cell repertoire and increasing IFN-γ to IL-10 ratio. Exp Parasitol. 2009;122(2):145-54.
43. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg. 1990;84(2):221-5. (Pubitemid 20172009)
44. Thakur CP, Olliaro P, Gothoskar S, Bhowmick S, Choudhury BK, Prasad S, Kumar M, Verma BB. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (paromomycin) antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg. 1992;86(6):615-6.
45. Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, Davidson RN. Epidemic visceral leishmaniasis in Sudan a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis. 1993;168(3):715-20.
46. Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet. 1994;344(8937):1599-600.
47. Thakur CP, Bhowmick S, Dolfi L, Olliaro P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg. 1995;89(2):219-23.
48. Jha TK, Singh NKP, Singh IJ, Jha S. Combination therapy in kala-azar. J Assoc Physicians India. 1995;43:319-20.
49. Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon gamma plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis. 1997;176(4):1117-9. (Pubitemid 27411065)
50. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Zaniewski AE, Houlihan HH, Olliaro P. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2000;94(4):429-31. (Pubitemid 30662355)
51. Das VN, Ranjan A, Sinha AN, Verma N, Lal CS, Gupta AK, Siddiqui NA, Kar SK. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J Assoc Physicians India. 2001;49:609-13. (Pubitemid 33702117)
52. Melaku Y, Colin SM, Keus K, Gatluak F, Retmeijer K, Davidson RN. Treatment of kala-azar in southern Sudan using a. 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg. 2007;77(1):89-94. (Pubitemid 351844356)
53. Biju SS, Talegaonkar S, Mishra PR, Khar RK. Vesicular systems: an overiew. Indian J Pharm. Sci. 2006;68(2):141-153.
54. Goldberg EP. Targeted drugs. 2nd ed. New York: Wiley; 1983. p. 312.
55. Bangham AD, Standish, MM, Watkins JG. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238-52.
56. Date AA, Joshi MD, Patravale VB. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev. 2007;59(6):505-21.
57. Ahsan F, Rivas IP, Khan MA, Torres Suárez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres on the phagocytosis by macrophages. J Control Release. 2002;79(1-3):29-40. (Pubitemid 34164159)
58. Romero EL, Morilla MJ. Drug delivery systems against leishmaniasis? Still an open question. Expert Opin Drug Deliv. 2008;5(7):805-23.
59. Papahadjopoulos D. Liposomes and their use in biology and medicine. Ann N Y Acad Sci. 1978;308:1-412.
60. Gregoriadis G, Florence AT. Liposomes in drug delivery: Clinical, diagnostic and ophthalmic potential. Drugs. 1993;45(1):15-28. (Pubitemid 23093890)
61. Goyal P, Kumar SGV, Goyal K, Singh A, Mishra DN, Katare OP. Liposomal drug delivery systems - clinical applications. Acta Pharma. 2005;55(1):1-25. (Pubitemid 40562616)
62. Kshirsagar NA, Pandya SK, Kirodian BG, Sanath S. Liposome drug delivery system from laboratory to clinic. J Postgrad Med. 2005; 51(suppl 1):S5-14.
63. Abra RM, Hunt CA. Liposome disposition in-vivo. III. Dose and vesicle-size effects. Biochim Biophys Acta. 1981;666(3):493-503
64. Alving CR, Weldon JS, Munnell JF. Liposomes in leishmaniasis: The lysosome connection. In: Gregoriadis G, Poste G, Senior J, Trouet A, editors. Receptor-mediated targeting of drugs. New York and London: Plenum Press; 1984. p. 317-31.
65. Vyas SP, Sihorkar V. Endogenous ligands and carriers in non-immunogenic site specific delivery. Adv Drug Deliev Rev. 2000;43(2-3):101-64.
66. Black CD, Watson GJ, Ward RJ. The use of Pentostam liposomes in the chemotherapy of experimental leishmaniasis. Trans R Soc Trop Med Hyg. 1977;71(6):550-2.
67. New RR, Chance ML, Thomas SC, Peters W. Anti-leishmanial activity of antimonials entrapped in liposomes. Nature. 1978;272(5648):55-6.
68. Alving CR, Steck EA, Chapman WL, Waits VB, Hendricks LD, Swartz GM Jr, Hanson WL. Therapy of leishmaniasis: superior efficacies of liposome encapsulated drugs (antimonial compounds/ phospholipids/model membranes/parasites). Proc Natl Acad Sci U S A. 1978;75(6):2959-63.
69. New RR, Chance ML, Heath S. Anti-leishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother. 1981;8(5):371-81
70. Chapman WL, Hanson WL, Alving CR, Hendricks LD. Anti-leishmanial activity of liposome-encapsulated meglumine antimoniate in the dog. Am J Vet Res. 1984;45(5):1028-30.
71. Berman JD, Ksionski G, Hanson WL, Chapman WL, Waits V B. Anti-leishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agent Chemother. 1986;30(6):847-51.
72. Croft SL, Davidson RN, Thornton EA. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother. 1991;28(suppl B):111-8.
73. Oliva G, Gradoni L, Ciaramella P, De Luna R, Cortese L, Orsini S, Davidson RN, Persechino A. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother. 1995;36(6):1013-9.
74. Derouin F, Gangneux JP, Sulahian A, Jean-Franqois Garin Yves. Lipid formulations of amphotericin B in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Trans R Soc Trop Med Hyg. 1996;90(5):574-7.
75. Paul M, Durand R, Fessi H, Rivollet D, Houin R, Astier A, Deniau M. Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Antimicrob Agents Chemother. 1997;41(8):1731-4.
76. Cauchetier E, Paul M, Rivollet D, Fessi H, Asteir A, Deniau M. Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis. Int J Parasitol. 2000;30(6):777-83.
77. Frezard F, Michalick MSM, Soares CF, Demicheli C. Novel methods for the encapsulation of meglumine antimoniate into liposomes. Braz J Med Biol Res. 2000;33(7):841-6. (Pubitemid 30604766)
78. Schettni DA, Costa Val AP, Souza LF, Demicheli C, Rocha OGF, Melo MN, Michalick MSM, Frezard F. Distribution of liposome-encapsulated antimony in dogs. Braz J Med Biol Res. 2003;36(2):269-72.
79. Tempone AG, Perez D, Rath S, Vilarinho AL, Mortara RA, de Andrade Jr HF. Targeting Leishmania chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine. J Antimicrob Chemother. 2004;54(1):60-8. (Pubitemid 39028968)
80. Schettini DA, Costa Val AP, Souza LF, Demicheli C, Rocha OGF, Melo MN, Michalick MSM, Frezard F. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome encapsulated meglumine antimoniate. Braz J Med Biol Res. 2005;38(12):1879-83. (Pubitemid 43078618)
81. Schettni DA, Ribeiro RR, Demicheli C, Rocha OGF, Melo MN, Michalick MSM, Frezard F. Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size. Int J Pharm. 2006;315(1-2):140-7. (Pubitemid 44275230)
82. Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, Scotti S, Cascio A, Castagnola E, Maisto A, Gramiccia M, di Caprio D, Wilkinson RJ, Bryceson ADM. Short-Course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis. 1996;22:938-43.
83. Thakur CP, Pandey AK, Sinha GP, Roy S, Olliaro P, Behbehani K. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg. 1996;90(3):319-22.
84. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ. 1998;76(1):25-32. (Pubitemid 28254976)
85. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomized trial. BMJ. 2001;323(7310):419-22. (Pubitemid 32801392)
86. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Low-Dose Liposomal Amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg. 2002;66(2):143-6. (Pubitemid 34755644)
87. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis. 2004;37(6):800-4.
88. Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis. 2008;47(8):1000-6.
89. ClinicalTrials.gov [homepage on the Internet]. Safety and efficacy study to evaluate different combination treatment regimens for visceral leishmaniasis. NCT00696969. [23 Feb. 2010, date last accessed]. Available from: http://clinicaltrials.gov/ct2/show/NCT00696969.
90. ClinicalTrials.gov [homepage on the Internet]. Short course of miltefosine and liposomal amphotericin B for kala-azar. NCT00371995. [23 Jan. 2010, date last accessed]. Available from: http://clinicaltrialsgov/ct2/show/ NCT00371995.
91. Miller CR, Bondurant B, McLean SD, Mc Govern KA, O'Brien DF. Liposome cell interactions in vitro: effect of liposome surface charge on binding and endocytosis of conventional and sterically stabilized liposomes. Biochem. 1998;37:12875-83.
92. Senior J H, Trimble KR, Maskiewicz R. Interaction of positively charged liposomes with blood: implications for their application in vivo. Bichim Biophys Acta. 1991;1070(1):173-9.
93. Cullis PR, Chonn A, Semple SC. Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. Adv Drug Deliv Rev. 1998;32(1-2):3-17.
94. Chakraborty R, Dasgupta D, Adhya S, Basu MK. Cationic liposome-encapsulated antisense oligonucleotide mediates efficient killing of intracellular Leishmania. J Biochem. 1999;340:393-6.
95. Dey T, Anam K, Afrin F, Ali N. Anti-leishmanial activities of stearylamine-bearing liposomes. Antimicrob Agents Chemother. 2000;44(6):1739-42.
96. Dasgupta D, Adhya S, Basu MK, The effect of beta tubulin specific antisense oligonucleotide, encapsulated in different cationic liposomes on the suppression of intracellular L. donovani parasites in vitro. J Biochem. 2002;132(1):23-7.
97. Pal S, Ravindran R, Ali N. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice. Antimicrob Agents Chemother. 2004;48(9):3591-3.
98. Banerjee A, De M, Ali N. Complete cure of experimental visceral leishmaniasis with amphotericin b in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J Immunol. 2008;181(2):1386-98.
99. Gupta S, Sane SA, Shakya N, Haq W. CpG oligodeoxynucleotide augments the anti-leishmanial activity of miltefosine against experimental visceral leishmaniasis. J Antimicrob Chemother. 2010;65(7):1448-54.
100. Ishiwata H, Suzuki N, Ando S, Kikuchi H, Kitagawa T. Characteristics and biodistribution of cationic liposomes and their DNA complexes. J Control Release. 2000;69:139-48.
101. Phillips NC. Filion MC. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta. 1997;1329:345-56.
102. Rojanasakul Y, Dokka S, Toledo D, Shi X, Castranova V. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharma Res. 2000;17(5):521-5. (Pubitemid 30416388)
103. Storm G, Woodle MC. Long-circulating liposome therapeutics: from concept to clinical reality. In: Woodle MC, Storm G, editors. Long circulating liposomes: old drugs, new therapeutics. Berlin: Springer; 1998. p. 3-16.
104. Blume GaCG. Molecular mechanism of the lipid vesicle longevity in vivo. Biochim Biophys Acta. 1993;1146:157-68.
105. Johnstone SA, Masin D, Mayer L, Bally MB. Surface associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta. 2001;1513:25-37. (Pubitemid 32566372)
106. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed. 2006;1(3):.297-315
107. Bakker-Woudenberg AJM Irma. Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci. Int J Antimicrob Agents. 2002;19(4): 299-311.
108. Proulx ME, Desormeaux A, Marquis J, Olivier M, Bergeron MG. Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob Agents Chemother. 2001;45:2623-7. (Pubitemid 32801920)
109. Antimisiaris SG. Arsonoliposomes for drug delivery applications. Clin Lipidology. 2009;4(5): 663-75.
110. V Dembitsky, D Levitsky. Arsenolipids. Prog Lipid Res. 2004;43(5):403-48.
111. Antimisiaris SG, Loannou PV, Loiseau PM. In-vitro anti-leishmanial and trypanocidal activities of arsonoliposomes and preliminary in-vivo distribution in BALB/c mice. J Pharm Pharmacol. 2003;55(5):647-52.
112. Antimisiaris SG, P Klepetsanis, V Zachariou, Giannopoulou E, Loannou PV, In-vivo distribution of arsenic after intraperitoneal injection of arsonoliposomes in BALB/c mice. Int J Pharm. 2005;289(1- 2):151-8. (Pubitemid 40093549)
113. Sihorkar V, Vyas SP. Potential of polysacchride anchored liposomes in drug delivery, targeting and immunization. J Pharma Pharmaceut Sci. 2001;4(2):138-58. (Pubitemid 34305606)
114. Najjar VA. Biological effects of tuftsin and its analogs. Drugs Future. 1987;12:147-160.
115. Fridkin M, Najjar VA. Tuftsin: its chemistry, biology, and clinical potential. Crit Rev Biochem Mol Biol. 1989;24(1):1-40.
116. Guru PY, Aggarwal AK, Singha UK, Singhal A, Gupta CM. Drug targeting in Leishmania donovani infections using tuftsin bearing liposomes as drug vehicles. FEBS Lett. 1989;245(1-2):204-8.
117. Das N, Mahato S, Naskar K, Ghosh D, Basu M. Targeting of urea stibamine encapsulated in liposomes to reticuloendothelial system for the treatment of experimental leishmaniasis. Biochem Med Metab Biol. 1990;43(2):133-9.
118. Kole L, Sarkar K, Mahato S, Das P. Neoglycoprotein conjugated liposomes as macrophage specific drug carrier in the therapy of leishmaniasis. Biochem Biophys Res Commun. 1994;200:351-8.
119. Banerjee G, Basu MK, Mahato SB, Nandi G, Pakrashi A. Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J Antimicrob Chemother. 1996;38(1):145-50.
120. Banerjee G, Medda S, Basu MK. A novel peptide-grafted liposomal delivery system targeted to macrophages. Antimicrob Agents Chemother. 1998;42(2):348-51. (Pubitemid 28114443)
121. Agrawal AK, Agrawal A, Pal A, Guru PY, Gupta CM. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J Drug Target. 2002;10(1):41-5. (Pubitemid 34223848)
122. Mitra M, Mandal AK, Chatterjee TK, Das N. Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasis. J Drug Target. 2005;13(5):286-93. (Pubitemid 41283162)
123. Dasgupta D, Chakraborty P, Basu MK. Ligation of Fc receptor of macrophages stimulates protein kinase C and anti-leishmanial activity. Mol Cell Biochem. 2000;209(1):1-8. (Pubitemid 30451429)
124. Mukherjee S, Das L, Kole L, Karmakkar S, Datta A, Das P. Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis. The J Infect Dis. 2004;189(6):1024-34. (Pubitemid 38373095)
125. Amselem S, Yogev A, Zawoznik E. Emulsomes, a novel drug delivery technology. Proceedings of the International Symposium on Controlled Release of Bioactive Materials. 1994;21:1368-9. (Pubitemid 24358348)
126. Amselem S, Friedman D. Solid fat nanoemulsions. United States Patent US 5662932; 1997.
127. Vyas SP. Macrophage targeting and colloidal drug carriers. In: Vyas SP, Dixit VK, editors. Advances in lipsomal research. New Delhi: CBS Publishers and Distributors; 2000. p. 98-120.
128. Gupta S, Dube A, Vyas SP. Anti-leishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target. 2007;15(3):437-44.
129. Uchegbu IF, Vyas S.P. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172(1-2):33-70.
130. Uchegbu I, Jeoma F, Florence A. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Coll Int Sci. 1995;58:1-55.
131. Jain CP, Arora R. Advances in niosome as a drug carrier: a review. Asian Journal of Pharmaceutics. 2007;1(1):29-39.
132. Baillie AJ, Coombs GH, Dolan TF, Laurie J Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol. 1986;38:502-5.
133. Carter KC, Baillie AJ, Alexander J, Dolan TF. The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent. J Pharm Pharmacol. 1988;40(5):370-3.
134. Carter KC, Dolan TF, Alexander J, Baillie AJ, McColganC. Visceral leishmaniasis: Drug Carrier System characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J Pharm Pharmacol. 1989;41(2):87-91.
135. Williams DM, Carter KC, Baillie AJ. Visceral Leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate. J Drug Target. 1995;3(1):1-7.
136. Hunter CA, Dolan TF, Coombs GH, Baillie AJ. Vesicular Systems (niosomes and liposomes) for delivery of sodium Stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol. 1988;40(3):161-5.
137. Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother. 1997;41(10):2089-92.
138. Mullen AB, Baillie AJ, Carter KC. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agents Chemother. 1998;42(10):2722-5.
139. Williams D, Mullen AB, Baillie AJ, Carter KC. Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. J Pharm Pharmacol. 1998;50(12):1351-6.
140. Carter KC, Baillie AJ, Mullen AB. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c Mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection. Immunology. 1999;6(1):61-5.
141. Carter KC, Muellen AB, Sundar S, Kenney RT. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani. Antimicrob Agents Chemother. 2001;45(12):3555-9.
142. Nieto J, Alvar J, Mullen AB, Carter KC, Rodriguez C, San Andres MI, San Andres MD, Baillie AJ, Gonzalez F. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob Agents Chemother. 2003;47(9):2781-7.
143. Carvalho PB, Arribas MAG, Ferreira EI. Leishmaniasis. What do we know about its chemotherapy? Rev Bras Ci Farm. 2000;36(suppl 1):69-96.
144. Sharma U, Velapandian T, Sharma P, Singh S. Evaluation of anti-leishmanial activity of selected Indian plants known to have antimicrobial properties. Parasitol Res. 2009;105(5):1287-93.
145. Weniger B, Robledo S, Arango GJ, Deharo E, Aragón R, Muñoz V, Callapa J, Lobstein A, Anton R. Antiprotozoal activities of Colombian plants. J Ethnopharmacol. 2001;78(2-3):193-200.
146. Banerjee G, Bhaduri AN, Basu MK. Mannose-coated liposomal hamycin in the treatment of experimental leishmaniasis in hamsters. Biochem Med Metabol Biol. 1994;53(1):1-7. (Pubitemid 24339013)
147. Medda S, Mukhopadhyay S, Basu MK. Evaluation of the in-vivo activity and toxicity of amarogentin, an anti-leishmanial agent in both liposomal and niosomal forms. J Antimicrob Chemother. 1999;44(6):791-4.
148. Raay B, Medda S, Mukhopadhyay S, Basu MK. Targeting of piperine intercalated in mannose coated liposomes in experimental leishmaniasis. Ind J Biochem Biophys. 1999;36(4):248-51. (Pubitemid 129486085)
149. Sinha J, Mukhopadhyay S, Das N, Basu MK. Targeting of liposomal andrographolide to L. donovani infected macrophages in-vivo. Drug Deliv. 2000;7(4):209-13. (Pubitemid 32057552)
150. Sarkar S, Mandal S, Sinha J, Mukhopadhyay S, Basu MK, Das N. Quercetin: Critical evaluationas an anti-leishmanial agent in-vivo in hamsters using different vesicular delivery modes. J Drug Target. 2002;10(8):573-8. (Pubitemid 36124356)
151. Sinha J, Raay B, Das N, Medda S , Garai S, Mahato SB, Basu MK. Bacopasaponin C: critical evaluation of anti-leishmanial properties in various delivery modes. Drug Deliv. 2002;9(1):55-62.
152. Lala S, Pramanick S, Mukhopadhyay S, bandhyopadhyay S, Basu MK. Harmine: evaluation of its anti-leishmanial properties in various vesicular delivery systems. J Drug Target. 2004;12(3): 165-75.
153. Ouellette M, Ward S. Drug resistance in parasites. In: Marr J, Nielsen T, Komuniecki R, editors. Molecular medical parasitology. San Diego: Academic Press; 2002. p. 395-430.
154. Mamot C, Drummond DC, Hong K. Liposome- based approaches to overcome anticancer drug resistance. Drug Resist Updat. 2003;6:271-9.
155. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007;2:16.
156. Forssen E, Willis M. Ligand-targeted liposomes. Adv Drug Deliv Rev. 1998;29:249-71.